Tell Your Story & You Could Win a Trip to NY Film Festival

Posted on: Thu, 05/28/2015 - 09:05 By: nrs-admin

Rosacea’s Impact Goes More than Skin Deep – Empower Yourself with the Facts and Break Up with Your Makeup For A Chance To Win A Trip To The New York Film Festival

Although an estimated 16 million Americans are dealing with rosacea day in and day out, many people are unaware of the emotional impact that this chronic, inflammatory skin disorder can have on sufferers. In fact, a national survey developed by Galderma Laboratories, L.P. in partnership with the National Rosacea Society revealed that many patients struggle with feeling unattractive (50 percent), embarrassed (42 percent) and less confident (30 percent). Patients consequently rely on makeup to cover up their symptoms - not knowing that some cosmetics may actually make things worse. To arm patients with facts about rosacea, empower them to seek help and inspire others to do the same by sharing their experiences, Galderma and the NRS have partnered to launch the Break Up with Your Makeup campaign.

Break Up with Your Makeup 

Break Up with Your Makeup is a national campaign that aims to educate consumers about the signs and symptoms of rosacea, how to proactively manage the condition and also empower them to feel as confident as possible about their skin. As part of this initiative, from now through June, eligible consumers are invited to submit a no makeup selfie and 100-word story through the Break Up with Your Makeup digital hub for the chance to win a trip to the New York Film Festival this fall. Be on the lookout for the top ten finalists to be announced later in the summer! Vote on your favorites to be entered into a sweepstakes for a chance to win one of three $500 gift card prizes.

Education on Rosacea Still Needed

As we know far too well, education on symptoms, triggers and treatment options is still needed. “Many patients with rosacea will initially come to my office thinking that they have acne or another skin condition, which they’ve been incorrectly treating with over-the-counter remedies and attempting to conceal with harsh makeups,” says Dr. Doris Day, nationally recognized dermatologist, campaign spokesperson and Galderma consultant. “Since rosacea manifests differently for each patient, it’s important for patients to speak with their physician about the treatment that’s right for them, as well as any emotional challenges they may be facing, so that they can feel as confident as possible.”

Treatment Options are Available

Galderma offers a broad portfolio of rosacea solutions that address a variety of frustrating symptoms for patients with the condition. Galderma currently markets topical Mirvaso® (brimonidine) topical gel, 0.33%* for the topical treatment of persistent (nontransient) facial erythema associated with rosacea in adults; systemic Oracea® Capsules, the only oral treatment approved by FDA for the inflammatory lesions (papulopustular) of rosacea in adults; and Soolantra® (ivermectin) Cream, 1%, the latest product in papulopustular rosacea treatment. In late December 2014, the FDA approved Soolantra® Cream, a once-daily, antibiotic-free product indicated for the treatment of inflammatory lesions, or bumps and pimples, of rosacea.

So please join the movement. Visit to get the facts about rosacea, learn more about the campaign and to enter the contest.  



Important Safety Information - Soolantra® Cream
Indication: Soolantra® (ivermectin) Cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Adverse Events: In clinical trials with Soolantra Cream, the most common adverse reactions (incidence ≤1%) included skin burning sensation and skin irritation. Warnings / Precautions: Not for oral, ophthalmic or intravaginal use. 

Important Safety Information - Mirvaso® Gel*
Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha-2 adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin-burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure.  Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease.  Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported.  Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

*Each gram of gel contains 5mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base

Important Safety Information - Oracea® Capsules
Indication: ORACEA® (doxycycline, USP) 40 mg** Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

**30 mg immediate release & 10 mg delayed release beads

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit WWW.FDA.GOV/MEDWATCH or call 1-800-FDA-1088. 

All trademarks are the property of their respective owners.